Sonoma Pharmaceuticals, Inc.
SNOA
$2.79
$0.8040.20%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 13.58% | 31.05% | -1.05% | 14.10% | 6.59% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.58% | 31.05% | -1.05% | 14.10% | 6.59% |
| Cost of Revenue | 36.71% | 27.40% | -6.21% | 9.21% | -20.59% |
| Gross Profit | -13.01% | 37.47% | 8.47% | 26.27% | 75.69% |
| SG&A Expenses | 10.04% | 2.59% | -5.19% | 15.52% | -36.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.39% | 12.44% | -2.21% | 16.51% | -16.66% |
| Operating Income | -22.16% | 29.64% | 5.40% | -22.84% | 53.98% |
| Income Before Tax | 0.43% | 64.33% | 31.29% | 5.56% | 51.55% |
| Income Tax Expenses | 115.79% | -20.97% | 542.42% | -122.90% | -267.65% |
| Earnings from Continuing Operations | -7.16% | 58.89% | 19.39% | 18.43% | 55.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.16% | 58.89% | 19.39% | 18.43% | 55.34% |
| EBIT | -22.16% | 29.64% | 5.40% | -22.84% | 53.98% |
| EBITDA | -24.91% | 29.92% | 5.10% | -22.91% | 55.66% |
| EPS Basic | 60.03% | 89.74% | 76.64% | 77.31% | 87.29% |
| Normalized Basic EPS | 62.87% | 91.10% | 80.08% | 73.73% | 86.21% |
| EPS Diluted | 60.03% | 89.74% | 76.64% | 77.31% | 87.29% |
| Normalized Diluted EPS | 62.87% | 91.10% | 80.08% | 73.73% | 86.21% |
| Average Basic Shares Outstanding | 168.13% | 300.78% | 245.02% | 259.47% | 251.35% |
| Average Diluted Shares Outstanding | 168.13% | 300.78% | 245.02% | 259.47% | 251.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
